Bevacizumab intraocular injection solution (Shanghai CP Guojian)

贝伐珠单抗眼内注射溶液（三生国健）

Report date: 2025/10/15 16:42:41

Base Information

Drug NameBevacizumab intraocular injection solution (Shanghai CP Guojian)
Drug Alias Name重组抗VEGF人源化单克隆抗体注射液（三生国健）Recombinant anti-VEGF monoclonal antibody (Shanghai CP Guojian)重组抗VEGF人源化单克隆抗体（三生国健）601A601a +[6] 
ClassificationBiologics
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsDiabetic macular oedemaChoroidal NeovascularizationRetinal Vein Occlusion +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsRetinal Vein OcclusionWet age-related macular degenerationMacular Edema
Inactive IndicationsDiabetic macular oedemaChoroidal NeovascularizationMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A